Cargando…

The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies

BACKGROUND: Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO−463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jun-Ping, Wang, Wen-Bo, Yang, Xiao-Xi, Yang, Lei, Ren, Li, Zhou, Fu-Xiang, Hu, Liu, He, Wei, Li, Bai-Yu, Zhu, Yan, Jiang, Huan-Gang, Zhou, Yun-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688689/
https://www.ncbi.nlm.nih.gov/pubmed/23840365
http://dx.doi.org/10.1371/journal.pone.0065778
_version_ 1782476244749647872
author Yang, Jun-Ping
Wang, Wen-Bo
Yang, Xiao-Xi
Yang, Lei
Ren, Li
Zhou, Fu-Xiang
Hu, Liu
He, Wei
Li, Bai-Yu
Zhu, Yan
Jiang, Huan-Gang
Zhou, Yun-Feng
author_facet Yang, Jun-Ping
Wang, Wen-Bo
Yang, Xiao-Xi
Yang, Lei
Ren, Li
Zhou, Fu-Xiang
Hu, Liu
He, Wei
Li, Bai-Yu
Zhu, Yan
Jiang, Huan-Gang
Zhou, Yun-Feng
author_sort Yang, Jun-Ping
collection PubMed
description BACKGROUND: Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO−463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association between the MPO−463G>A polymorphism and lung cancer risk remains controversial. METHOD: To investigate the effect of this polymorphism on lung cancer susceptibility, we performed a meta-analysis based on 22 published case–control studies including 7,520 patients with lung cancer and 8,600 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. RESULTS: Overall, there was no evidence for significant association between MPO−463G>A polymorphism and lung cancer susceptibility (for AA versus GG: OR = 0.91, 95%CI = 0.67–1.24; for GA versus GG: OR = 0.87, 95% CI = 0.78–0.98; for AA/GA versus GG: OR = 0.90, 95% CI = 0.80–1.01; for AA versus GA/GG: OR = 0.96, 95% CI = 0.72–1.28). In the stratified analyses by ethnicity, source of controls and smoking status, we also did not find any significant association between them. CONCLUSIONS: In summary, this meta-analysis suggests MPO−463G>A polymorphism may not be a risk factor for developing lung cancer. However, further prospective well-designed population-based studies with larger sample size are expected to validate the results.
format Online
Article
Text
id pubmed-3688689
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36886892013-07-09 The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies Yang, Jun-Ping Wang, Wen-Bo Yang, Xiao-Xi Yang, Lei Ren, Li Zhou, Fu-Xiang Hu, Liu He, Wei Li, Bai-Yu Zhu, Yan Jiang, Huan-Gang Zhou, Yun-Feng PLoS One Research Article BACKGROUND: Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO−463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association between the MPO−463G>A polymorphism and lung cancer risk remains controversial. METHOD: To investigate the effect of this polymorphism on lung cancer susceptibility, we performed a meta-analysis based on 22 published case–control studies including 7,520 patients with lung cancer and 8,600 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. RESULTS: Overall, there was no evidence for significant association between MPO−463G>A polymorphism and lung cancer susceptibility (for AA versus GG: OR = 0.91, 95%CI = 0.67–1.24; for GA versus GG: OR = 0.87, 95% CI = 0.78–0.98; for AA/GA versus GG: OR = 0.90, 95% CI = 0.80–1.01; for AA versus GA/GG: OR = 0.96, 95% CI = 0.72–1.28). In the stratified analyses by ethnicity, source of controls and smoking status, we also did not find any significant association between them. CONCLUSIONS: In summary, this meta-analysis suggests MPO−463G>A polymorphism may not be a risk factor for developing lung cancer. However, further prospective well-designed population-based studies with larger sample size are expected to validate the results. Public Library of Science 2013-06-20 /pmc/articles/PMC3688689/ /pubmed/23840365 http://dx.doi.org/10.1371/journal.pone.0065778 Text en © 2013 Yang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Yang, Jun-Ping
Wang, Wen-Bo
Yang, Xiao-Xi
Yang, Lei
Ren, Li
Zhou, Fu-Xiang
Hu, Liu
He, Wei
Li, Bai-Yu
Zhu, Yan
Jiang, Huan-Gang
Zhou, Yun-Feng
The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies
title The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies
title_full The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies
title_fullStr The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies
title_full_unstemmed The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies
title_short The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies
title_sort mpo−463g>a polymorphism and lung cancer risk: a meta-analysis based on 22 case–control studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688689/
https://www.ncbi.nlm.nih.gov/pubmed/23840365
http://dx.doi.org/10.1371/journal.pone.0065778
work_keys_str_mv AT yangjunping thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT wangwenbo thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT yangxiaoxi thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT yanglei thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT renli thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT zhoufuxiang thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT huliu thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT hewei thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT libaiyu thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT zhuyan thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT jianghuangang thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT zhouyunfeng thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT yangjunping mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT wangwenbo mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT yangxiaoxi mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT yanglei mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT renli mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT zhoufuxiang mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT huliu mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT hewei mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT libaiyu mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT zhuyan mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT jianghuangang mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies
AT zhouyunfeng mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies